SEC Tracker
Get the app
BTAIQ · XBRL financial data

BioXcel Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BTAIQ's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers341376*5821,104214366*16812098256*206182
Cost of goods and services sold512714*80621,170832*141071132*28322
Research and development19,6199,934*11,4018,0325,1015,901*4,55410,2568,7406,701*2,9553,164
Selling, general and administrative24,3449,603*13,2649,4507,6834,094*5,6995,6095,3813,805*7,1917,189
Operating income (loss)(48,297)(19,875)*(24,163)(17,296)(15,293)(10,493)*(10,099)(15,852)(14,228)(10,282)*(10,223)(10,193)
Interest income1,068946*947671616368*279230236321*211131
Interest expense3,2523,435*3,6073,7003,7904,032*3,9934,2224,3734,396*4,1984,257
Other income (expense)(5)108*3212,0264,8173,298*6,559657(12,546)1,812*1,519(394)
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(50,486)(22,256)*(26,791)(8,299)(13,650)(10,859)*(7,254)(19,187)(30,911)(12,545)*(12,691)(14,713)
Earnings per share, basic USD per share(1.72)(0.76)*(0.87)(0.21)(0.32)—(1.50)(2.45)(2.18)—(0.54)(0.49)
Earnings per share, diluted USD per share(1.72)—(0.87)(0.21)(0.32)—(1.50)(2.45)(2.18)—(0.54)(0.49)
Weighted average shares, basic thousands of shares29,26829,434*30,86840,25342,390—4,8347,84314,196—23,57130,300
Weighted average shares, diluted thousands of shares29,268—30,86840,25342,390—4,8347,84314,196—23,57130,300
  • † Share count changed about 1/8 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (BTAIQ's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents89,96165,22174,14156,27140,38729,85431,01317,43536,17628,41517,18012,841
Inventory2,0181,9912,4392,6801,525679642506459722500483
Prepaid and other current assets3,8532,7822,1032,7754,4795,2904,7375,1505,6904,0283,9453,074
Total current assets98,73872,14380,91764,18147,79237,39437,77725,24344,40344,68533,90828,700
Property and equipment, net86278470662955247539932424917511799
Right-of-use asset7626886135384613823032221405600
Total assets100,44973,70282,32365,43548,89238,33838,56625,78944,79244,91634,02528,799
Accounts payable10,66913,65417,22013,25614,88915,99015,45016,69216,27614,70116,24718,783
Accrued liabilities26,61012,42413,67513,48510,1935,7623,9865,0904,3634,3416,3883,921
Current portion of long-term debt—————05,60811,21616,82324,93122,431104,451
Total current liabilities39,40827,26731,48127,28825,55722,23325,54633,37637,80453,92654,994137,149
Long-term debt99,093100,598101,633103,006104,440102,50899,91897,46992,30284,66377,8580
Lease liability, non-current52944035025616165——00——
Total liabilities141,057130,210154,686139,736134,525131,439128,738133,456133,711140,379139,568144,259
Accumulated deficit(568,342)(590,598)(617,389)(625,688)(639,338)(650,197)(657,451)(676,638)(707,549)(720,094)(732,785)(747,498)
Total stockholders' equity(40,608)(56,508)(72,363)(74,301)(85,633)(93,101)(90,172)(107,667)(88,919)(95,463)(105,543)(115,460)
Total liabilities and equity100,44973,70282,32365,43548,89238,33838,56625,78944,79244,91634,02528,799
Common shares outstanding (cover page) thousands of shares29,27330,57737,53140,74442,7485,4866,05614,55721,86927,07530,87831,305
  • † Share count changed about 1/8 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (BTAIQ's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(50,486)(22,256)*(26,791)(8,299)(13,650)(10,859)*(7,254)(19,187)(30,911)(12,545)*(12,691)(14,713)
Stock-based compensation4,014*3,599*3,4331,057*1,865*(199)*1801,556*581*450*435358*
Net cash from operating activities(37,584)*(26,863)*(17,706)(23,174)*(16,338)*(14,809)*(12,043)(12,575)*(18,787)*(14,210)*(11,809)(6,098)*
Purchases of property and equipment0*0*——0*0*00*0*0*00*
Net cash from investing activities0*0*——0*0*00*0*0*00*
Proceeds from issuing common stock0*2,375*——————————
Proceeds from issuing equity————4677,001*46713,679*38,234*5,762*8,4983,109*
Repayments of long-term debt—————year only00*—year only8,108304*
Net cash from financing activities0*2,123*26,6265,304*454*4,276*13,202137*37,532*5,647*2322,719*
Net change in cash(37,584)*(24,740)*8,920(17,870)*(15,884)*(10,533)*1,159(12,438)*18,745*(8,563)*(11,577)(3,379)*
  • † Share count changed about 1/8 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
BioXcel Therapeutics12,841182(6,098)*31.3M2.1 quarters 10-QJun 30, 2026
Phio Pharmaceuticals12,996not reported(4,035)*11.6M3.2 quarters 10-QJun 30, 2026
Palisade Bio125,172500(7,603)*174.3M16.5 quarters 10-QJun 30, 2026
Citius Pharmaceuticals17,0081,494(8,678)*27.5M2.0 quarters 10-QJun 30, 2026
Brainstorm Cell Therapeutics22not reported(895)11.0M0.0 quarters 10-QJun 30, 2026
Cocrystal Pharma2,169105(2,516)*19.3M0.9 quarters 10-QJun 30, 2026
Kiora Pharmaceuticals7,077not reported(1,892)*4.4M8.9 quarters 10-QJun 30, 2026
Scienture Holdings8,188344(3,132)*41.1M2.6 quarters 10-QJun 30, 2026
Cypherpunk Technologies7,624not reported(2,692)*107.8M2.8 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.